Gerlinde Teuber
Overview
Explore the profile of Gerlinde Teuber including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
31
Citations
392
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Cornberg M, Stoehr A, Naumann U, Teuber G, Klinker H, Lutz T, et al.
Viruses
. 2022 Jul;
14(7).
PMID: 35891520
Using data from the German Hepatitis C-Registry (Deutsche Hepatitis C-Register, DHC-R), we report the real-world safety and effectiveness of glecaprevir/pibrentasvir (GLE/PIB) treatment and its impact on patient-reported outcomes (PROs) in...
2.
Kruger K, Rossol S, Krauth C, Buggisch P, Mauss S, Stoehr A, et al.
Z Gastroenterol
. 2022 Jul;
61(5):489-503.
PMID: 35839795
Background & Aims: With long-term consequences like the development of liver cirrhosis and hepatocellular carcinoma, chronic hepatitis C virus (HCV) infection is associated with a significant health burden. Information on...
3.
Huppe D, Stoehr A, Buggisch P, Mauss S, Klinker H, Teuber G, et al.
J Viral Hepat
. 2021 Aug;
28(10):1474-1483.
PMID: 34339561
The number of patients diagnosed with hepatitis C virus (HCV) is markedly higher than the number initiating treatment indicating gaps in the care cascade, likely centred around reaching at-risk populations....
4.
Stein K, Stoehr A, Klinker H, Teuber G, Naumann U, John C, et al.
Eur J Gastroenterol Hepatol
. 2020 Sep;
34(1):76-83.
PMID: 32956186
Objectives: Grazoprevir/elbasvir and glecaprevir/pibrentasvir (G/P) are the two preferred treatment options for patients with chronic hepatitis C virus (HCV) infection and a glomerular filtration rate (GFR) <30 mL/min. Both therapies...
5.
Vermehren J, Serfert Y, Cornberg M, Stoehr A, Klinker H, Simon K, et al.
Z Gastroenterol
. 2020 Sep;
58(9):841-846.
PMID: 32947629
Despite the high effectiveness of direct-acting antivirals for the treatment of hepatitis C, a small proportion of patients do not respond to approved regimens. The combination regimen of SOF/VEL/VOX was...
6.
Traussnigg S, Schattenberg J, Demir M, Wiegand J, Geier A, Teuber G, et al.
Lancet Gastroenterol Hepatol
. 2019 Jul;
4(10):781-793.
PMID: 31345778
Background: Norursodeoxycholic acid is an orally administered side chain-shortened homologue of ursodeoxycholic acid that undergoes hepatic enrichment with hepatoprotective, anti-inflammatory, and antifibrotic activity. We assessed the efficacy of two doses...
7.
Berg T, Naumann U, Stoehr A, Sick C, John C, Teuber G, et al.
Aliment Pharmacol Ther
. 2019 Mar;
49(8):1052-1059.
PMID: 30874328
Background: Glecaprevir/pibrentasvir is a pangenotypic direct-acting antiviral regimen approved for treating adults chronically infected with hepatitis C virus (HCV). There are limited real-world data on glecaprevir/pibrentasvir to date. Aim: To...
8.
Buggisch P, Vermehren J, Mauss S, Gunther R, Schott E, Pathil A, et al.
J Hepatol
. 2017 Nov;
68(4):663-671.
PMID: 29133244
Background & Aims: Ledipasvir/sofosbuvir (LDV/SOF) for 8 to 24 weeks is approved for the treatment of chronic hepatitis C virus infection (HCV). In the ION-3 study, 8 weeks of LDV/SOF...
9.
Heidrich B, Wiegand S, Buggisch P, Hinrichsen H, Link R, Moller B, et al.
PLoS One
. 2014 Oct;
9(10):e108751.
PMID: 25302676
Evidence based clinical guidelines are implemented to treat patients efficiently that include efficacy, tolerability but also health economic considerations. This is of particular relevance to the new direct acting antiviral...
10.
Stahmeyer J, Rossol S, Bert F, Antoni C, Demir M, Hinrichsen H, et al.
Eur J Gastroenterol Hepatol
. 2014 Aug;
26(11):1278-85.
PMID: 25144493
Background: Viral hepatitis is major a public health problem affecting millions of people worldwide. Estimates assume 400 000-500 000 people chronically infected with hepatitis C virus (HCV) in Germany. Long-term...